Early experience with intravenous sotalol in children with and without congenital heart disease.
Early experience with intravenous sotalol in children with and without congenital heart disease.
复制标题
患有和不患有先天性心脏病的儿童静脉注射索他洛尔的早期经验。
DOI：
10.1016/j.hrthm.2018.07.010
复制
发表时间：
2018
期刊：
影响因子：
5.5
通讯作者：
Kim,JeffreyJ
中科院分区：
文献类型：
--
作者：
Valdés,SantiagoO;Miyake,ChristinaY;Niu,MaryC;delaUz,CaridadM;Asaki,SYukiko;Landstrom,AndrewP;Schneider,AndrewE;Rusin,CraigG;Patel,Raajen;Lam,WilsonW;Kim,JeffreyJ
研究背景心律失常在儿科人群中很常见。在不能口服药物或需要急性治疗的患者中，静脉（IV）抗凝药物的选择有限。最近，IV索他洛尔已成为现成的，但在儿童的经验是limited.<$The本研究的目的是描述我们的初步经验与使用IV索他洛尔在pediatric population.MethodsA回顾性研究所有儿科患者接受IV索他洛尔进行。患者人口统计学特征、先天性心脏病的存在、心律失常类型、IV索他洛尔使用的疗效，结果共47例患者（26例（55%）男性和24例（51%）先天性心脏病）接受静脉注射索他洛尔，中位年龄为2.05岁（四分位数范围0.07-10.03岁），中位体重为12.8 kg（四分位数范围3.8-34.2 kg），13例（28%）在急性术后环境中接受IV索他洛尔。室上性心律失常40例（85%），室性心动过速7例（15%）。在24例接受IV索他洛尔治疗活动性心律失常的患者中，21例（88%）实现了急性终止。23例患者因无法口服抗心律失常药物而接受IV索他洛尔作为复发性心律失常的维持治疗; 19例（83%）患者接受索他洛尔单药治疗后病情得到控制。没有病人需要停止IV索他洛尔继发不良反应，促心律失常，或QT delaying.ConclusionIV索他洛尔是一种有效的抗心律失常的选择，为儿科患者，并可能是一个很好的代理急性终止活动性心律失常。耐受性良好，没有患者因不良反应而需要停药。
BackgroundArrhythmias are common in the pediatric population. In patients unable to take oral medications or in need of acute therapy, options of intravenous (IV) antiarrhythmic medications are limited. Recently IV sotalol has become readily available, but experience in children is limited.ObjectiveThe purpose of this study was to describe our initial experience with the use of IV sotalol in the pediatric population.MethodsA retrospective study of all pediatric patients receiving IV sotalol was performed. Patient demographic characteristics, presence of congenital heart disease, arrhythmia type, efficacy of IV sotalol use, and adverse effects were evaluated.ResultsA total of 47 patients (26 (55%) male and 24 (51%) with congenital heart disease) received IV sotalol at a median age of 2.05 years (interquartile range 0.07–10.03 years) and a median weight of 12.8 kg (interquartile range 3.8–34.2 kg), and 13 (28%) received IV sotalol in the acute postoperative setting. Supraventricular arrhythmias occurred in 40 patients (85%) and ventricular tachycardia in 7 (15%). Among 24 patients receiving IV sotalol for an active arrhythmia, acute termination was achieved in 21 (88%). Twenty-three patients received IV sotalol as maintenance therapy for recurrent arrhythmias owing to inability to take oral antiarrhythmic medications; 19 (83%) were controlled with sotalol monotherapy. No patient required discontinuation of IV sotalol secondary to adverse effects, proarrhythmia, or QT prolongation.ConclusionIV sotalol is an effective antiarrhythmic option for pediatric patients and may be an excellent agent for acute termination of active arrhythmias. It was well tolerated, with no patient requiring discontinuation secondary to adverse effects.
登录
查看更多内容
制定安全的静脉注射索他洛尔给药方案
影响因子：
4.2
作者：
J. Somberg;R. Preston;V. Ranade;J. Molnar
通讯作者：
J. Molnar
DOI：
10.1016/s0735-1097(01)01272-4
发表时间：
2001-04-01
影响因子：
24
作者：
Warnes, CA;Liberthson, R;Webb, GD
通讯作者：
Webb, GD
口服索他洛尔治疗小儿心律失常的有效性。
DOI：
10.1016/0002-9149(92)90500-x
发表时间：
1992
期刊：
The American journal of cardiology
影响因子：
--
作者：
P. Maragnès;M. Tipple;A. Fournier
通讯作者：
A. Fournier
静脉注射和口服索他洛尔后 QT 延长与血清索他洛尔浓度高度相关
DOI：
--
发表时间：
2010
期刊：
The Cardiology
影响因子：
--
作者：
J. Somberg;R. Preston;V. Ranade;J. Molnar
通讯作者：
J. Molnar
维拉帕米反应性持续性室性心动过速导致幼儿严重心室功能障碍：口服维拉帕米的成功治疗。
影响因子：
5.7
作者：
Jae;B. Kim;Jeong
通讯作者：
Jeong